Abstract
The potential of antigen-directed cancer immunotherapy has not been fully realized, perhaps because many commonly targeted tumor associated proteins are not essential to maintaining the malignant cell phenotype. A constitutively activating mutation in the signaling molecule BRAF is expressed frequently in melanomas and may play an important role in the biology of this disease. A 29-mer B-Raf peptide incorporating the V599E mutation was used for in vitro stimulation of lymphocytes derived from melanoma patients, generating MHC class II-restricted CD4(+) T cells specific for this peptide as well as for melanoma cells expressing B-Raf V599E. Mutated B-Raf exemplifies targets that may be ideal for immunotherapy.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Alleles
-
Amino Acid Sequence
-
CD4-Positive T-Lymphocytes / immunology*
-
HLA-DP Antigens / genetics
-
HLA-DP beta-Chains
-
HLA-DQ Antigens / genetics
-
HLA-DQ beta-Chains
-
HLA-DR Antigens / genetics
-
HLA-DRB1 Chains
-
Humans
-
Melanoma / genetics*
-
Melanoma / immunology
-
Molecular Sequence Data
-
Mutation*
-
Proto-Oncogene Proteins B-raf
-
Proto-Oncogene Proteins c-raf / chemistry
-
Proto-Oncogene Proteins c-raf / genetics*
-
Proto-Oncogene Proteins c-raf / immunology
-
Sequence Analysis, DNA
Substances
-
HLA-DP Antigens
-
HLA-DP beta-Chains
-
HLA-DPB1 antigen
-
HLA-DQ Antigens
-
HLA-DQ beta-Chains
-
HLA-DQB1 antigen
-
HLA-DR Antigens
-
HLA-DRB1 Chains
-
BRAF protein, human
-
Proto-Oncogene Proteins B-raf
-
Proto-Oncogene Proteins c-raf